PROSTATE cancer medicine Xofigo (radium-223 dichloride) should not be used with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination, according to a recommendation made by the European Medicines Agency (EMA).
EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate cancer patients.
There was a slightly higher mortality rate in treated versus controls ( 35% vs 28%) while fractures also occurred more frequently with the Xofigo combination than the placebo combination (26% versus 8.1%).
Go to ema.europa.eu for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 18
